Source: International Congress 2017 – Clinical challenges in chronic lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
T. Greulich (Marburg, Germany). Safety of bi-weekly intravenous therapy with alpha-1 antitrypsin. 710

Member's Comments

No comment yet.

Related content which might interest you: Safety and tolerability of aerosolized human alpha-1 antitrypsin (AAT): a phase Ia/Ib clinical study Source: Annual Congress 2008 - Novel experimental approaches to understanding asthma and COPD II Year: 2008 Effects of biweekly Alpha1 antitrypsin replacement therapy: a case series Source: Virtual Congress 2020 – Clinical and basic pharmacology for COPD Year: 2020 Substitution therapy in Alpha-1 antitrypsin deficiency after lung transplantation Source: Eur Respir J 2006; 28: Suppl. 50, 724s Year: 2006 Population pharmacokinetics of A1-PI in patients with Alpha-1 antitrypsin deficiency Source: International Congress 2015 – New data on established treatments for COPD Year: 2015 Integrated safety across six clinical trials of alpha-1 augmentation therapy Source: International Congress 2014 – Novel evidence relating to respiratory treatment development Year: 2014 Effect of intravenous alpha-1-antitrypsin augmentation therapy on proteinase-3-generated AaVal541 in deficient patients Source: Virtual Congress 2021 – Airway pharmacology: translational and basic science Year: 2021 Therapeutic efficacy of alpha-1 antitrypsin (AAT) augmentation therapy on the loss of lung tissue: an integrated analysis Source: Annual Congress 2008 - Recent advances in the pathogenesis and treatment of asthma and COPD Year: 2008 Homecare setting of longterm augmentation therapy in alpha1 antitrypsin defiency patients leads to clinical stabilization Source: International Congress 2017 – New frontiers in home care management of chronic lung diseases Year: 2017 i.v. iron improves efficacy of ESA therapy with Darbepoetin alfa for patients with chemotherapy-induced anaemia Source: Breathe 2008; 4: 364 Year: 2008 Effects of a-1 antitrypsin augmentation therapy and a-1 antitrypsin deficiency in pneumococcal pneumonia in mice Source: International Congress 2019 – Advances in COPD pharmacology Year: 2019 Implementation of screening program for alpha-1 antitrypsin deficiency in Spain Source: Annual Congress 2004 - Emphysema and oxygen therapy Year: 2004 A well-designed/conducted study on alpha-1 antitrypsin epidemiology not quoted Source: Eur Respir J, 51 (3) 1702662; 10.1183/13993003.02662-2017 Year: 2018 The withdrawal of replacement therapy and outcomes in alpha-1 antitrypsin deficiency lung transplant recipients Source: Eur Respir J, 53 (5) 1900055; 10.1183/13993003.00055-2019 Year: 2019 Safety of bi-weekly infusion of A1-PI augmentation therapy in RAPID Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015 Regional deposition of 99mTc-labelled alpha-1 antitrypsin (AAT) in patients with alpha-1 antitrypsin deficiency and cystic fibrosis (CF) compared with healthy volunteers Source: Annual Congress 2007 - Cystic fibrosis: the balance between treatment and side-effects Year: 2007 Safety, immunogenicity and pharmacokinetics (PK) of a 120 mg/kg/week dose of alpha1-proteinase inhibitor in alpha1-antitrypsin deficiency Source: Annual Congress 2013 –COPD drugs: new findings Year: 2013 Evaluation of antituberculous drugs administration Source: Eur Respir J 2002; 20: Suppl. 38, 547s Year: 2002